請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61445
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學(Ming-Shyue Lee) | |
dc.contributor.author | Sheng-Ta Chung | en |
dc.contributor.author | 鍾昇達 | zh_TW |
dc.date.accessioned | 2021-06-16T13:03:11Z | - |
dc.date.available | 2018-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-05 | |
dc.identifier.citation | 1. de Cuba, E.M., et al., Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. Virchows Arch, 2012. 461(3): p. 231-43.
2. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 74-108. 3. Shinya, H. and W.I. Wolff, Morphology, anatomic distribution and cancer potential of colonic polyps. Ann Surg, 1979. 190(6): p. 679-83. 4. Bird, N.C., D. Mangnall, and A.W. Majeed, Biology of colorectal liver metastases: A review. J Surg Oncol, 2006. 94(1): p. 68-80. 5. Koppe, M.J., et al., Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg, 2006. 243(2): p. 212-22. 6. Carvalho, B., et al., Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol (Dordr), 2012. 35(1): p. 53-63. 7. Gupta, G.P. and J. Massague, Cancer metastasis: building a framework. Cell, 2006. 127(4): p. 679-95. 8. Joyce, J.A. and J.W. Pollard, Microenvironmental regulation of metastasis. Nat Rev Cancer, 2009. 9(4): p. 239-52. 9. Wu, S.R., et al., Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol, 2010. 177(6): p. 3145-58. 10. Sternlicht, M.D. and Z. Werb, How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol, 2001. 17: p. 463-516. 11. Orlichenko, L.S. and D.C. Radisky, Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis, 2008. 25(6): p. 593-600. 12. Dove, A., MMP inhibitors: glimmers of hope amidst clinical failures. Nat Med, 2002. 8(2): p. 95. 13. Netzel-Arnett, S., et al., Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev, 2003. 22(2-3): p. 237-58. 14. Noel, A., et al., Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol, 2004. 57(6): p. 577-84. 15. Ono, M. and M. Kuwano, Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res, 2006. 12(24): p. 7242-51. 16. Wheeler, D.L., E.F. Dunn, and P.M. Harari, Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol, 2010. 7(9): p. 493-507. 17. Baselga, J. and S.M. Swain, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer, 2009. 9(7): p. 463-75. 18. Hsuan, J.J., Oncogene regulation by growth factors. Anticancer Res, 1993. 13(6B): p. 2521-32. 19. Marmor, M.D., K.B. Skaria, and Y. Yarden, Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 2004. 58(3): p. 903-13. 20. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumorigenesis. Cell, 1990. 61(5): p. 759-67. 21. de Castro-Carpeno, J., et al., EGFR and colon cancer: a clinical view. Clin Transl Oncol, 2008. 10(1): p. 6-13. 22. Spano, J.P., et al., Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol, 2005. 16(2): p. 189-94. 23. Nicholson, R.I., J.M. Gee, and M.E. Harper, EGFR and cancer prognosis. Eur J Cancer, 2001. 37 Suppl 4: p. S9-15. 24. Lockhart, A.C. and J.D. Berlin, The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol, 2005. 32(1): p. 52-60. 25. Voldborg, B.R., et al., Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol, 1997. 8(12): p. 1197-206. 26. Shi, Y.E., et al., Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res, 1993. 53(6): p. 1409-15. 27. Takeuchi, T., M.A. Shuman, and C.S. Craik, Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A, 1999. 96(20): p. 11054-61. 28. Zhang, Y., et al., Assignment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-->q25 by in situ hybridization. Cytogenet Cell Genet, 1998. 83(1-2): p. 56-7. 29. Tanimoto, H., et al., Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol, 2001. 22(2): p. 104-14. 30. Kim, M.G., et al., Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics, 1999. 49(5): p. 420-8. 31. Lee, M.S., et al., Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain. Am J Physiol Cell Physiol, 2007. 293(1): p. C95-105. 32. Kim, C., et al., Filamin is essential for shedding of the transmembrane serine protease, epithin. EMBO Rep, 2005. 6(11): p. 1045-51. 33. Oberst, M.D., et al., The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem, 2003. 278(29): p. 26773-9. 34. Benaud, C., R.B. Dickson, and C.Y. Lin, Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem, 2001. 268(5): p. 1439-47. 35. Cho, E.G., R.H. Schwartz, and M.G. Kim, Shedding of membrane epithin is blocked without LDLRA4 and its protease activation site. Biochem Biophys Res Commun, 2005. 327(1): p. 328-34. 36. Uhland, K., Matriptase and its putative role in cancer. Cell Mol Life Sci, 2006. 63(24): p. 2968-78. 37. List, K., et al., Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev, 2005. 19(16): p. 1934-50. 38. Oberst, M.D., et al., Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res, 2002. 8(4): p. 1101-7. 39. Riddick, A.C., et al., Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer, 2005. 92(12): p. 2171-80. 40. Saleem, M., et al., A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev, 2006. 15(2): p. 217-27. 41. Kang, J.Y., et al., Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res, 2003. 63(5): p. 1101-5. 42. Santin, A.D., et al., The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer, 2003. 98(9): p. 1898-904. 43. Benaud, C.M., et al., Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis, 2002. 19(7): p. 639-49. 44. Oberst, M., et al., Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol, 2001. 158(4): p. 1301-11. 45. Lucas, J.M., et al., The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol, 2008. 215(2): p. 118-25. 46. Vaarala, M.H., et al., The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int J Cancer, 2001. 94(5): p. 705-10. 47. Paoloni-Giacobino, A., et al., Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics, 1997. 44(3): p. 309-20. 48. Wilson, S., et al., The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J, 2005. 388(Pt 3): p. 967-72. 49. Bottcher, E., et al., Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol, 2006. 80(19): p. 9896-8. 50. Yu, J., et al., An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 2010. 17(5): p. 443-54. 51. Afar, D.E., et al., Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res, 2001. 61(4): p. 1686-92. 52. Morikawa, K., et al., Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res, 1988. 48(23): p. 6863-71. 53. Morikawa, K., et al., In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res, 1988. 48(7): p. 1943-8. 54. Kiyomiya, K., et al., Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol, 2006. 291(1): p. C40-9. 55. Doger, F.K., et al., Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur Surg Res, 2006. 38(6): p. 540-4. 56. Kim, S., et al., EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal, 2009. 21(6): p. 892-8. 57. Binker, M.G., et al., EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2. Biochem Biophys Res Commun, 2009. 379(2): p. 445-50. 58. Shima, I., et al., Expression of epidermal growth-factor (EGF), matrix metalloproteinase-9 (mmp-9) and proliferating cell nuclear antigen (pcna) in esophageal cancer. Int J Oncol, 1995. 6(4): p. 833-9. 59. Tarin, D., Clinical and experimental studies on the biology of metastasis. Biochim Biophys Acta, 1985. 780(3): p. 227-35. 60. Chattopadhyay, S. and V.I. Shubayev, MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway. Glia, 2009. 57(12): p. 1316-25. 61. Ingraham, C.A., et al., Matrix metalloproteinase (MMP)-9 induced by Wnt signaling increases the proliferation and migration of embryonic neural stem cells at low O2 levels. J Biol Chem, 2011. 286(20): p. 17649-57. 62. Bocheva, G., et al., Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer. J Invest Dermatol, 2009. 129(7): p. 1816-23. 63. Galkin, A.V., et al., CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate, 2004. 61(3): p. 228-35. 64. MS, L., Matrix-degrading Type II transmembrane serine protease matriptase: its role in cancer development and malignancy. Journal of Cancer Molecules, 2006. 5 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61445 | - |
dc.description.abstract | 失調的致癌基因訊息或細胞外緣的蛋白分解酶作用被認為與癌症的侵襲和轉移是有著莫大關係。在本篇研究中,我們利用一組人類大腸癌惡化轉移細胞模式,包括KM12C, KM12-L4, KM12-SM細胞,探討表皮生長因子受器(EGFR)、及兩種第二型嵌膜絲氨酸蛋白酶[間質蛋白酶 (Matriptase)和TMPRSS2]在大腸癌細胞侵襲中扮演的角色。我們的結果指出表皮生長因子受器的蛋白質表達量及其磷酸化程度、間質蛋白酶及TMPRSS2的活性,在具高轉移侵襲力的大腸癌KM-L4和KM12-SM細胞中,均明顯的增加,並與細胞的侵襲能力,呈現正相關。利用基因大量表達或剔除的實驗,結果發現表皮生長因子受器、間質蛋白酶及TMPRSS2,均參與EGF所誘發增加的大腸癌細胞侵襲能力。當大量表達TMPRSS2在大腸癌細胞時,間質蛋白酶的活性會隨之增加,但過量表達間質蛋白酶卻不會造成TMPRSS2的活化。此結果顯示在大腸癌細胞中TMPRSS2是間質蛋白酶的上游調控分子。同時,從抑制劑的實驗發現,EGF可以透過活化PI3K/AKT訊息,進而活化間質蛋白酶及促進大腸癌細胞侵襲力的上升。綜合上述的結果,發現在大腸癌細胞中,表皮生長因子訊息可經由PI3K/AKT或驅動TMPRSS2的活化,進而促進間質蛋白酶活性的上升,造成癌細胞移動侵襲能力的增加。 | zh_TW |
dc.description.abstract | Dysregulation of oncogenic signaling or proteolysis on cell surface has been proposed to play an important role in cancer cell invasion and metastasis. In this study, I delineated the roles of EGFR, matriptase and TMPRSS2 in colorectal cancer cell invasion, using a human colorectal cancer metastasis progression model (KM12C, KM12-L4 and KM12-SM cells). KM12-L4 and KM12-SM cells are two cell lines established from KM12C cells, and exhibited higher invasion and metastasis potentials than KM12C cells. My results showed that the protein and tyrosine phosphorylation levels of EGFR were dramatically increased in KM12-L4 and KM12-SM cells in comparison of KM12C cells, which were concurrent with the high levels of activated matriptase and TMPRSS2. With overexpression or knockdown approaches, the results indicated that EGFR, matriptase and TMPRSS2 were involved in colorectal cancer cell invasion. Moreover, my data further indicated that EGF could stimulate colorectal cancer cell invasion, matriptase and TMPRSS2 activation. TMPRSS2 overexpression could increase the activated levels of matriptase while matriptase overexpression had no effect on TMPRSS2, suggesting a proteolytic cascade from TMPRSS2 to matriptase. In addition, EGF-induced matriptase activation was at least partly via PI3K but not MEK/Erk1/2 signaling. Taken together, the data indicate that EGFR signaling can be through PI3K/AKT or TMPRSS2 to induce matriptase activation, leading to increasing colorectal cancer cell invasion. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:03:11Z (GMT). No. of bitstreams: 1 ntu-102-R00442018-1.pdf: 10472407 bytes, checksum: 9b74ace0edc7fc24bce9ab4192e09e53 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Contents
誌謝 I 中文摘要 III Abstarct IV Chapter1. Introduction 1 1.1 Colorectal cancer 2 1.2 Cancer metastasis 2 1.3 EGFR signaling and colorectal cancer development 3 1.4 Matriptase 6 1.5 TMPRSS2 11 1.6 Research motivation 14 Chapter 2. Materils and methods 15 2.1 Materials 16 2.2 Mothods 22 2.3 Buffers 34 2.4 Table 38 Chapter 3. Results 40 3.1 Colorectal cancer cell progression model 41 3.2 Cell invasion, migration and growth of KM12C, KM12-L4 and KM12-SM cells 42 3.3 Protein and mRNA levels of EGFR in the colorectal cancer metastasis progression model 43 3.4 Activities of MMPs and matriptase in human colorectal cancer cell progression model 44 3.5 Effects of EGF on KM12C cell invasion and migration 45 3.6 Effect of EGF on EGFR activation and the activated levels of matriptase in KM12C cells 46 3.7 Effect of EGF treatment on MMP-2 and MMP-9 activity in KM12C cells 46 3.8 Effect of EGFR knockdown on the invasion of KM12C and KM12-SM cells 47 3.9Effect of matriptase knockdown on the colorectal cancer cell invasion 47 3.10 Establishment of stable matriptase-overexpressing KM12C cell pools 48 3.11 Analysis of TMPRSS2 in the colorectal cancer cells 49 3.12 Effect of EGF on the activated levels of TMPRSS2 in KM12C cells 50 3.13 Involvement of TMPRSS2 in colorectal cancer cell invasion 50 3.14 Effects of TMPRSS2 overexpression on KM12C cell invaion 51 3.15 TMPRSS2 can promote matriptase activation in KM12C cells 52 3.16 Role of TMPRSS2 in matriptase activation in colorectal cancer cells 52 3.17 Increases of matriptase shedding by TMPRSS2 53 3.18 Identification of Erk1/2 or PI3K/AKT signaling that mediated EGF effect on inducing matriptase activation in KM12C cells 54 3.19 Proposed model of EGF-induced colorectal cancer cell invasion via activation of TMPRSS2 and matriptase. 54 Chapter 4. Discussion 56 Chapter 5. Figures 62 Chapter 6. Refrences 96 | |
dc.language.iso | en | |
dc.title | 間質蛋白酶在表皮生長因子所誘發的大腸癌細胞侵襲移動力中扮演角色 | zh_TW |
dc.title | Matriptase is involved in EGF-induced colorectal cancer cell invasion | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林敬哲(Jing-Jer Lin),黃祥博(Hsiang-Po Huang),郭明良(Min-Liang Kuo) | |
dc.subject.keyword | 表皮生長因子,間質蛋白酶,TMPRSS2,大腸癌,轉移, | zh_TW |
dc.subject.keyword | EGFR,matriptase,TMPRSS2,colorectal cancer,metastasis, | en |
dc.relation.page | 103 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-06 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 10.23 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。